Australia: Life Sciences' New Frontier

Chief Executive Officer

BioCina

Aug 28, 2025PAO-08-25-BIO-06

Biologics - Large Molecule PA TV (video)

Mark W. Womack, CEO of BioCina, and Ben McLeod discuss the unique advantages Australia offers for biotech innovators and manufacturers, including government-sponsored tax incentives and best-in-class infrastructure.

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-19Jul 20, 2026

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

PAO-07-26-PA-04Jul 7, 2026

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-17Jul 6, 2026

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-24Jun 15, 2026

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

PAO-06-26-CL-01Jun 10, 2026

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-06-26-PA-04Jun 8, 2026

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

PAO-06-26-PA-01Jun 2, 2026

NGIB

Rethinking Fermentation: Halophiles and the Next Generation of Industrial Biotechnology

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-05May 18, 2026

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-04May 4, 2026

Carbon Footprint

Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma

Jimin Han

Samsung Biologics

PAO-05-26-CL-01Apr 30, 2026

PAT

Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-11Apr 16, 2026

PAT

From Analytical Visibility to Real-Time Control in Biologics Purification

David Alvaro, Ph.D.

Pharma's Almanac

PAO-04-26-PA-10Apr 15, 2026

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Australia: Life Sciences' New Frontier

Related Content

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

NGIB

Rethinking Fermentation: Halophiles and the Next Generation of Industrial Biotechnology

David Alvaro, Ph.D.

Pharma's Almanac

ADC Engineering

Engineering Antibodies for Precision Payload Delivery

David Alvaro, Ph.D.

Pharma's Almanac

Carbon Footprint

Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma

Jimin Han

Samsung Biologics

PAT

Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up

David Alvaro, Ph.D.

Pharma's Almanac

PAT

From Analytical Visibility to Real-Time Control in Biologics Purification

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

AI-Optimized CLD

From Screening to Design: Can Production Cell Lines Become Programmable Platforms?

David Alvaro, Ph.D.

Pharma's Almanac

Drug–Device

Designing Formulations Around Devices Rather Than Vice Versa

Pharma's Almanac

Protein Conformation

Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

NGIB